CHLORPROMAZINE may leads to lower leaving the study early compared with PLACEBO (low certainty).
It is very uncertain whether CHLORPROMAZINE changes leaving the study early compared with HALOPERIDOL (very low certainty).
It is very uncertain whether chlorpromazine changes leaving the study early: for any reason compared with clotiapine (very low certainty).
It is very uncertain whether chlorpromazine changes leaving the study early ‐ for any reason compared with piperacetazine (very low certainty).
CHLORPROMAZINE showed no clear difference in leaving the study early ‐ due to adverse effects (short term) compared with RESERPINE (moderate certainty).
CHLORPROMAZINE showed no clear difference in leaving the study early due to any reason short term (up to 6 months) compared with QUETIAPINE (moderate certainty).
It is very uncertain whether CHLORPROMAZINE changes leaving the study early due to any reason: short term (up to 6 months) compared with OLANZAPINE (very low certainty).
It is very uncertain whether CHLORPROMAZINE changes leaving the study early due to adverse effects ‐ short term (up to 6… compared with RISPERIDONE (very low certainty).
CHLORPROMAZINE LOW DOSE (≤ 400 mg/day) probably leads to lower leaving the study early ‐ any reason compared with HIGH DOSE (> 800 mg/day ‐ all medium term) (moderate certainty).
CHLORPROMAZINE LOW DOSE (≤ 400 mg/day) showed no clear difference in leaving the study early ‐ any reason compared with MEDIUM DOSE (401 mg/day to 800 mg/day) (moderate certainty).
Zuclopenthixol dihydrochloride may leads to lower leaving the study early (any reason) compared with chlorpromazine (low certainty).
The intervention showed no clear difference in leaving the study early: any reason (medium term) (low certainty).